Welcome to our dedicated page for Niagen Bioscience news (Ticker: NAGE), a resource for investors and traders seeking the latest updates and insights on Niagen Bioscience stock.
Niagen Bioscience, Inc. (NASDAQ: NAGE) is a bioscience company focused on NAD+ (nicotinamide adenine dinucleotide) science and healthy aging, and its news flow reflects that specialization. Company announcements frequently highlight developments around its patented nicotinamide riboside ingredient Niagen®, the Tru Niagen® consumer supplement line, and the Niagen Plus™ intravenous and injectable platform.
Readers following NAGE news can expect updates on product launches and line extensions, such as Tru Niagen Beauty, which combines Niagen with clinically studied ingredients to support the appearance of hair, skin, and nails. News items also cover commercial partnerships and distribution milestones, including the expansion of pharmaceutical-grade Niagen Plus IV and injections into hundreds of clinics and wellness centers across the United States.
Because Niagen Bioscience emphasizes evidence-based positioning, a significant portion of its news relates to clinical and scientific progress. This includes publication of randomized controlled trials using Niagen in specific populations, summaries of peer-reviewed research on NAD+ biology, and the evolution of educational platforms like AboutNAD®, which curates NAD+ research for consumers, clinicians, and scientists.
Investors and observers will also find regular coverage of financial and corporate developments, such as quarterly earnings releases, changes to full-year outlook, share repurchase authorizations, and intellectual property transactions involving core nicotinamide riboside patents. For anyone tracking the NAD+ category, the NAGE news page offers an ongoing view into how Niagen Bioscience advances its science, expands its product ecosystem, and manages its capital and IP strategy. Bookmark this page to monitor new studies, product initiatives, and regulatory or market updates that the company discloses over time.
Niagen Bioscience (NASDAQ: NAGE) announced U.S. Patent No. 12,558,367 covering methods of use for nicotinamide riboside (Niagen) in intravenous and injectable formulations, with expected protection through 2044. The patent covers aqueous IV formulations, administration parameters, select NR salt forms, and combination uses.
According to the company, the grant strengthens its IP moat for IV/injectable NAD+ precursors, supports commercial expansion and partnerships, and complements a portfolio of over 100 patents; Niagen IV is available at more than 1,200 U.S. clinics.
Niagen Bioscience (NASDAQ: NAGE) is the premiere sponsor of the inaugural NAD for Health: Opportunities & Challenges conference hosted by the University of Copenhagen, March 23–25, 2026. The three-day scientific forum will gather researchers, clinicians, and industry to advance NAD+ translation, trial design, and biomarkers.
Niagen Bioscience (NASDAQ: NAGE) will report fourth quarter and full year 2025 financial results after market close on Wednesday, March 4, 2026. Management will host an investor conference call the same day at 4:30 p.m. ET to review results and provide a business update.
The live webcast and dial-in will be available, with replay from 7:30 p.m. ET on March 4, 2026 through 11:59 p.m. ET on March 11, 2026. Call participants are asked to join at least 10 minutes early.
Niagen Bioscience (NASDAQ: NAGE) announced that qualified customers can now purchase Tru Niagen® on www.truniagen.com using HSA/FSA funds via a Truemed Letter of Medical Necessity (LMN) issued by a licensed provider.
The partnership with Truemed enables a streamlined checkout for one-time purchases or reimbursement for subscriptions, with approved LMNs valid for 12 months; HSA/FSA eligibility and tax savings vary by account.
Niagen Bioscience (NASDAQ: NAGE) announced on December 22, 2025 that it acquired the core nicotinamide riboside (NR) patent portfolio from Queen’s University Belfast, making Niagen the sole owner of foundational NR intellectual property.
The portfolio includes composition-of-matter patents (including U.S. Patent No. 12,252,506 covering multiple NR salt forms such as NR Malate and NR Tartrate), methods of making NR, and global rights across multiple jurisdictions. Niagen says the move strengthens its >90 issued and pending patents estate, including >50 focused on NR, and provides greater strategic, operational and licensing optionality for current and future pharmaceutical and other applications.
Niagen Bioscience (NASDAQ: NAGE) launched Tru Niagen® Beauty, the first U.S. NAD+ skincare supplement featuring Niagen (patented nicotinamide riboside).
Each capsule delivers 100 mg Niagen plus clinically studied actives: Astaxanthin 4 mg, Hyaluronic acid 120 mg, Grape seed extract 100 mg, Biotin 5 mg, and Vitamin E 30 mg. The product is sold at $62 one-time or $49.60 subscription, with bundles combining Tru Niagen 300 mg and Tru Niagen Pro 1,000 mg. Tru Niagen Beauty ships direct at truniagen.com and will launch on the healthcare practitioner channel on February 2, 2026. Market context includes astaxanthin and nutricosmetics growth projections cited for industry demand.
Niagen Bioscience (NASDAQ: NAGE) reported results from a randomized, double-blind, placebo-controlled trial (58 participants) published in eClinicalMedicine on November 13, 2025 testing Niagen® nicotinamide riboside (NR) in long COVID. Participants received 2,000 mg/day NR for 20 weeks (placebo 10 weeks then NR 10 weeks). Whole-blood NAD+ levels rose up to 3.1-fold after 5–10 weeks. Post-hoc within-group improvements were seen in fatigue, sleep quality, and depressive symptoms after 10 weeks. No statistically significant differences were observed between NR and placebo for primary or secondary endpoints, and the study cited limited power due to small sample size and dropouts. NR was well tolerated with no significant adverse-event differences.
Niagen Bioscience (NASDAQ: NAGE) announced that its Board approved a $10 million share repurchase program to buy back common stock over approximately 24 months. The company may repurchase shares in the open market, through privately negotiated transactions, or by other means, subject to law and market conditions. Timing, method, pricing, and amounts will be determined by management and there is no obligation to repurchase shares. The Program may be modified, suspended, or terminated at any time without prior notice. Management described the Program as a compelling use of company capital. For more information, visit the company website.
Niagen Bioscience (NASDAQ:NAGE) reported third-quarter 2025 results with net sales up 33% to $34.0M and Tru Niagen sales $26.0M (+44%). Net income was $4.6M ($0.06/share) versus $1.9M a year ago, and Adjusted EBITDA rose 120% to $6.4M. Cash from operations for the nine months was $12.8M, with quarter-end cash of $64.3M. The company reaffirmed and raised full-year 2025 net sales guidance to +25%–30% YoY. Operational highlights include the launch of the AboutNAD digital platform, a favorable National Advertising Division decision, and expansion of Niagen Plus distribution to >1,000 clinics. Updated expense outlooks include higher G&A ($8.0–$9.0M).
Niagen Bioscience (NASDAQ: NAGE) will report third quarter 2025 financial results for the period ended September 30, 2025, after market close on Tuesday, November 4, 2025. Management will host an investor conference call on Tuesday, November 4, 2025 at 4:30 p.m. ET to discuss the results and provide a general business update.
Call participants should dial in at least 10 minutes early. Toll-free dial-in: +1 888 596 4144 with Conference ID 8584242. A live webcast will be available on the company investor relations site and a replay will be available from 7:30 p.m. ET on November 4, 2025 through 11:59 p.m. ET on November 11, 2025 (toll-free replay +1 800 770 2030, Replay ID 8584242).